Recent News

• 05.24.2025 - SpringWorks Therapeutics krijgt positief advies van de CHMP voor Mirdametinib voor de behandeling van volwassen en pediatrische patiënten met NF1-PN
• 05.24.2025 - SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN
• 05.24.2025 - SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN
• 05.24.2025 - SpringWorks Therapeutics: CHMP valuta positivamente Mirdametinib per il trattamento di pazienti adulti e pediatrici affetti da NF1-PN
• 05.24.2025 - SpringWorks Therapeutics recibe un dictamen positivo del CHMP para el uso de mirdametinib en el tratamiento de la NF1-NP en pacientes adultos y pediátricos
• 05.23.2025 - SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
• 05.23.2025 - SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
• 05.23.2025 - SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
• 04.28.2025 - Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
• 04.28.2025 - Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Recent Filings

• 05.15.2025 - PREM14A Preliminary proxy statements relating to merger or acquisition
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.14.2025 - 8-K Current report
• 05.09.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors